Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relief Therapeutics Hldg Ag (OP: RLFTF )

3.400 -0.450 (-11.69%)
Streaming Delayed Price Updated: 10:40 AM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relief Therapeutics Hldg Ag

< Previous 1 2 3 4 5 6 7 Next >
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
GENEVA, SWITZERLAND / ACCESSWIRE / June 2, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
NRx Pharmaceuticals (NASDAQ: NRXP) has applied with FDA requesting Emergency Use Authorization (EUA) for Zyesami (Aviptadil-acetate) for critically ill COVID-19... 
Via Benzinga
Exposures COVID-19 Product Safety
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
GENEVA, SWITZERLAND / ACCESSWIRE / May 28, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
GENEVA, SWITZERLAND / ACCESSWIRE / May 27, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
GENEVA, SWITZERLAND / ACCESSWIRE / May 18, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
GENEVA, SWITZERLAND / ACCESSWIRE / May 17, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Review Of Present Therapies For Covid-19
A summary of authorized drugs for Covid-19, those in development, and those that have failed. 
Via Talk Markets
Exposures COVID-19
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs GENEVA and BALERNA, SWITZERLAND / ACCESSWIRE / May 4, 2021 / RELIEF THERAPEUTICS Holding... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief and AdVita Announce Initiation of Phase 2 Trial with Inhaled RLF-100 for the Prevention of COVID-19-related Acute Respiratory Distress Syndrome
Investigator-sponsored trial being conducted at major medical centers in Switzerland Relief provides update on RLF-100 clinical development in Europe GENEVA, SWITZERLAND, and GUNDELFINGEN, GERMANY /... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
GENEVA, SWITZERLAND / ACCESSWIRE / April 19, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), commented today on certain statements made by NeuroRx, Inc., its... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
Relief Reports 2020 Financial Results and Provides Business Update
GENEVA, SWITZERLAND / ACCESSWIRE / April 15, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19 Product Safety
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
GENEVA, SWITZERLAND / ACCESSWIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100TM... 
From Relief Therapeutics Holdings AG
Via AccessWire
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.